JP2018501286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018501286A5 JP2018501286A5 JP2017536293A JP2017536293A JP2018501286A5 JP 2018501286 A5 JP2018501286 A5 JP 2018501286A5 JP 2017536293 A JP2017536293 A JP 2017536293A JP 2017536293 A JP2017536293 A JP 2017536293A JP 2018501286 A5 JP2018501286 A5 JP 2018501286A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- independently selected
- halo
- optionally substituted
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *C(*)(C1(*)N)N=C(*)N1C(*)=O Chemical compound *C(*)(C1(*)N)N=C(*)N1C(*)=O 0.000 description 4
- PZBPWAVSDAFKKR-UHFFFAOYSA-N C(C1)CC1N(CC1)CCN1C1=NC2(CCCC2)CN1 Chemical compound C(C1)CC1N(CC1)CCN1C1=NC2(CCCC2)CN1 PZBPWAVSDAFKKR-UHFFFAOYSA-N 0.000 description 2
- GGJMDVULWOPZFJ-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C2CC(C)C2)=NCC1)(O)=O Chemical compound CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C2CC(C)C2)=NCC1)(O)=O GGJMDVULWOPZFJ-UHFFFAOYSA-N 0.000 description 2
- DGZAKXCWCBQAJB-KRWDZBQOSA-N CC(C)c(cc1)ccc1S(N1C(N(CC2)C[C@H](C)N2C2CCC2)=NCC1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(N1C(N(CC2)C[C@H](C)N2C2CCC2)=NCC1)(=O)=O DGZAKXCWCBQAJB-KRWDZBQOSA-N 0.000 description 2
- NDELGZAEHZEGGT-UHFFFAOYSA-N CC(C)c(cc1)ccc1S=O Chemical compound CC(C)c(cc1)ccc1S=O NDELGZAEHZEGGT-UHFFFAOYSA-N 0.000 description 2
- IKDOSGHNSMKIPF-INIZCTEOSA-N CCN(CC1)CCN1C1=N[C@@H](C)CN1S(c1ccc(C(C)C)cc1)(=O)=O Chemical compound CCN(CC1)CCN1C1=N[C@@H](C)CN1S(c1ccc(C(C)C)cc1)(=O)=O IKDOSGHNSMKIPF-INIZCTEOSA-N 0.000 description 2
- IKDOSGHNSMKIPF-MRXNPFEDSA-N CCN(CC1)CCN1C1=N[C@H](C)CN1S(c1ccc(C(C)C)cc1)(=O)=O Chemical compound CCN(CC1)CCN1C1=N[C@H](C)CN1S(c1ccc(C(C)C)cc1)(=O)=O IKDOSGHNSMKIPF-MRXNPFEDSA-N 0.000 description 2
- DEOQQQJGUNGFJA-UHFFFAOYSA-N N#Cc(cc1)cc(cc2)c1cc2S(N1C(N(CC2)CCN2C2CCC2)=NCC1)(=O)=O Chemical compound N#Cc(cc1)cc(cc2)c1cc2S(N1C(N(CC2)CCN2C2CCC2)=NCC1)(=O)=O DEOQQQJGUNGFJA-UHFFFAOYSA-N 0.000 description 2
- NFIMKBZSGOEJID-UHFFFAOYSA-N O=S(c1cc(C2CC2)ccc1)(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O Chemical compound O=S(c1cc(C2CC2)ccc1)(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O NFIMKBZSGOEJID-UHFFFAOYSA-N 0.000 description 2
- QLKHAYOVBMNNDH-UHFFFAOYSA-N O=S(c1ccc(C2CC2)cc1)(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O Chemical compound O=S(c1ccc(C2CC2)cc1)(N1C(N(CC2)CCN2C2CCC2)=NCC1)=O QLKHAYOVBMNNDH-UHFFFAOYSA-N 0.000 description 2
- OYWRUFONTHFTPV-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1cc(O)ccc1 Chemical compound CC(C)(C)c(cc1)ccc1-c1cc(O)ccc1 OYWRUFONTHFTPV-UHFFFAOYSA-N 0.000 description 1
- SXARRWWXCNNPHR-UHFFFAOYSA-N CC(C)(C)c(cc1)ccc1-c1cccc(C(F)(F)F)c1 Chemical compound CC(C)(C)c(cc1)ccc1-c1cccc(C(F)(F)F)c1 SXARRWWXCNNPHR-UHFFFAOYSA-N 0.000 description 1
- LNHMZPLJAKHRAF-UHFFFAOYSA-N CC(C)c(cc1)ccc1/S(/N1C(N2CCN(CC3C(C)C3)CC2)=NCC1)=C(\C)/O Chemical compound CC(C)c(cc1)ccc1/S(/N1C(N2CCN(CC3C(C)C3)CC2)=NCC1)=C(\C)/O LNHMZPLJAKHRAF-UHFFFAOYSA-N 0.000 description 1
- JCZZXBBNDUHTEO-QFIPXVFZSA-N CC(C)c(cc1)ccc1S(N(C1)C(N(CC2)CCN2C2CCC2)=N[C@@H]1C1CC1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(N(C1)C(N(CC2)CCN2C2CCC2)=N[C@@H]1C1CC1)(=O)=O JCZZXBBNDUHTEO-QFIPXVFZSA-N 0.000 description 1
- FXTAEGNWBKAXQS-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C(C2)CC2F)=NCC1)(=O)=O Chemical compound CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C(C2)CC2F)=NCC1)(=O)=O FXTAEGNWBKAXQS-UHFFFAOYSA-N 0.000 description 1
- XLEPOKYVAIYKGC-UHFFFAOYSA-N CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C(C2)CC2F)=NCC1)(OC)=O Chemical compound CC(C)c(cc1)ccc1S(N1C(N(CC2)CCN2C(C2)CC2F)=NCC1)(OC)=O XLEPOKYVAIYKGC-UHFFFAOYSA-N 0.000 description 1
- AGYQXVAHSOSUQM-UHFFFAOYSA-N CC(C)c(cc1)ccc1SN1C(N2CCN(CC3C(C)C3)CC2)=NCC1 Chemical compound CC(C)c(cc1)ccc1SN1C(N2CCN(CC3C(C)C3)CC2)=NCC1 AGYQXVAHSOSUQM-UHFFFAOYSA-N 0.000 description 1
- CODOLAGGHAFSES-UHFFFAOYSA-N CCN(CC1)CCN1C1=NCCN1S(C1=CC(C(F)(F)F)=CCC1)(O)=O Chemical compound CCN(CC1)CCN1C1=NCCN1S(C1=CC(C(F)(F)F)=CCC1)(O)=O CODOLAGGHAFSES-UHFFFAOYSA-N 0.000 description 1
- CIVJDIMNCLSVNQ-UHFFFAOYSA-N CCN(CC1)CC[N-]1C1=NCCN1S(c1cccc(OC(F)(F)F)c1)=O Chemical compound CCN(CC1)CC[N-]1C1=NCCN1S(c1cccc(OC(F)(F)F)c1)=O CIVJDIMNCLSVNQ-UHFFFAOYSA-N 0.000 description 1
- DDZACMDGXVXOOH-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1O Chemical compound Cc(cc1)ccc1-c(cc1)ccc1O DDZACMDGXVXOOH-UHFFFAOYSA-N 0.000 description 1
- ZZFKRTRYOSBWQY-UHFFFAOYSA-N Cc(cc1)ccc1-c(cccc1)c1O Chemical compound Cc(cc1)ccc1-c(cccc1)c1O ZZFKRTRYOSBWQY-UHFFFAOYSA-N 0.000 description 1
- DBGGJDWYVIWOIA-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccc(C(F)(F)F)cc1 Chemical compound Cc(cc1)ccc1-c1ccc(C(F)(F)F)cc1 DBGGJDWYVIWOIA-UHFFFAOYSA-N 0.000 description 1
- GVVICDFSXZKAPO-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccccc1C(F)(F)F Chemical compound Cc(cc1)ccc1-c1ccccc1C(F)(F)F GVVICDFSXZKAPO-UHFFFAOYSA-N 0.000 description 1
- KUZNURGIXXKBEJ-UHFFFAOYSA-N Cc(cc1)ccc1-c1cccnc1 Chemical compound Cc(cc1)ccc1-c1cccnc1 KUZNURGIXXKBEJ-UHFFFAOYSA-N 0.000 description 1
- MRAIVJPPOXSJNG-UHFFFAOYSA-N Cc(cc1)ccc1-c1ccncc1 Chemical compound Cc(cc1)ccc1-c1ccncc1 MRAIVJPPOXSJNG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101933P | 2015-01-09 | 2015-01-09 | |
| US62/101,933 | 2015-01-09 | ||
| PCT/US2016/012588 WO2016112251A1 (en) | 2015-01-09 | 2016-01-08 | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018501286A JP2018501286A (ja) | 2018-01-18 |
| JP2018501286A5 true JP2018501286A5 (enExample) | 2019-02-14 |
| JP6889661B2 JP6889661B2 (ja) | 2021-06-18 |
Family
ID=55300775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017536293A Expired - Fee Related JP6889661B2 (ja) | 2015-01-09 | 2016-01-08 | ４，５−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ（ｋｄｍ２ｂ）インヒビターとしてのその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10202354B2 (enExample) |
| EP (1) | EP3242875B1 (enExample) |
| JP (1) | JP6889661B2 (enExample) |
| CN (1) | CN107406418B (enExample) |
| WO (1) | WO2016112251A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
| ES2912276T3 (es) * | 2015-04-07 | 2022-05-25 | Ela Pharma Ltd | Composiciones para tratar y/o prevenir necrosis celular o tisular que seleccionan como diana específicamente catepsina C y/o CELA1 y/o CELA3A y/o enzimas estructuralmente relacionadas con las mismas |
| WO2018132825A2 (en) * | 2017-01-16 | 2018-07-19 | Memorial Sloan Kettering Cancer Center | Treatment of sarcoma |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CU22545A1 (es) | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
| US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
| DE69025946T2 (de) | 1989-09-08 | 1996-10-17 | Univ Duke | Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
| ATE207366T1 (de) | 1993-12-24 | 2001-11-15 | Merck Patent Gmbh | Immunokonjugate |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| KR100441557B1 (ko) | 1994-07-21 | 2005-08-05 | 아크조 노벨 엔.브이. | 고리형케톤과산화물조성물 |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| CA2222231A1 (en) | 1995-06-07 | 1996-12-19 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth of tumors |
| PL188959B1 (pl) | 1995-07-06 | 2005-05-31 | Novartis Ag | Pirolopirymidyny i sposoby ich wytwarzania |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CN100503580C (zh) | 1996-04-12 | 2009-06-24 | 沃尼尔·朗伯公司 | 酪氨酸激酶的不可逆抑制剂 |
| US6391874B1 (en) | 1996-07-13 | 2002-05-21 | Smithkline Beecham Corporation | Fused heterocyclic compounds as protein tyrosine kinase inhibitors |
| ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| AU7165698A (en) | 1997-05-06 | 1998-11-27 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
| ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
| AU1308799A (en) | 1997-11-06 | 1999-05-31 | American Cyanamid Company | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
| CN1160338C (zh) | 1998-11-19 | 2004-08-04 | 沃尼尔·朗伯公司 | N-[4-(3-氯-4-氟-苯基氨基)-7-(3-吗啉-4-基-丙氧基)-喹唑啉-6-基]-丙烯酰胺,不可逆的酪氨酸激酶抑制剂 |
| CN101316823B (zh) * | 2005-12-01 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物 |
| EP2097386A2 (en) * | 2006-11-27 | 2009-09-09 | Novartis AG | Substituted dihydroimidazoles and their use in the treatment of tumors |
| US7897602B2 (en) * | 2009-01-12 | 2011-03-01 | Development Center For Biotechnology | Indolinone compounds as kinase inhibitors |
| EP2698367A1 (en) * | 2012-08-14 | 2014-02-19 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Benzimidazoles for the treatment of cancer |
| CA2903081A1 (en) * | 2013-03-14 | 2014-09-25 | Quanticel Pharmaceuticals, Inc. | Histone demethylase inhibitors |
| ES2644828T3 (es) * | 2013-03-15 | 2017-11-30 | Quanticel Pharmaceuticals Inc | Inhibidores de histona desmetilasa |
| EP3242875B1 (en) | 2015-01-09 | 2022-02-23 | Genentech, Inc. | 4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors |
-
2016
- 2016-01-08 EP EP16702999.0A patent/EP3242875B1/en active Active
- 2016-01-08 JP JP2017536293A patent/JP6889661B2/ja not_active Expired - Fee Related
- 2016-01-08 CN CN201680014129.5A patent/CN107406418B/zh not_active Expired - Fee Related
- 2016-01-08 WO PCT/US2016/012588 patent/WO2016112251A1/en not_active Ceased
-
2017
- 2017-07-07 US US15/643,805 patent/US10202354B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20241341A1 (es) | Compuestos terapeuticos para la infeccion por el virus vih | |
| TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
| PE20231441A1 (es) | Cocristal de un inhibidor de cdk | |
| JP2005519908A5 (enExample) | ||
| RU2403247C2 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов альфа 7 и их терапевтические применения | |
| RU2006135111A (ru) | Производные тиазола | |
| RU2018106453A (ru) | Соединения | |
| CA2713025A1 (en) | Kappa selective opioid receptor antagonist | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| RU2009121775A (ru) | Пиридильное неароматическое азот-содержащее гетероцикло-1-карбоксилатное производное | |
| JP2009536620A5 (enExample) | ||
| CA2416274A1 (en) | N-phenyl-2-pyrimidine-amine derivatives | |
| RU2007116119A (ru) | Производные циклоспорина, замещенные 3-эфиром и 3-тиоэфиром, для лечения и профилактики инфекционного гепатита с | |
| JP2014511892A5 (enExample) | ||
| RU2012156844A (ru) | Апоптоз-индуцирующие средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| CA2445341A1 (en) | Anthranilamides, process for their preparation, their use as antiarrhythmics, and pharmaceutical preparations thereof | |
| RU2018102449A (ru) | Производные пиразоло[1,5-a]триазин-4-амина, применимые в терапии | |
| RU2007101309A (ru) | Боросодержащее соединение и способы применения | |
| RU2014141674A (ru) | 3,5-диаминопиразоловые ингибиторы киназы | |
| JP2010517946A5 (enExample) | ||
| RU2015150120A (ru) | Соединение дикарбоновой кислоты | |
| RU2016134130A (ru) | ПИРАЗОЛО[1,5-а]ПИРИМИДИНЫ В КАЧЕСТВЕ ПРОТИВОВИРУСНЫХ СОЕДИНЕНИЙ | |
| RU2007122485A (ru) | Ингибиторы киназы | |
| RU2012108423A (ru) | Ацилгуанидиновые производные с азотсодержащим циклом | |
| RU2008143703A (ru) | ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА |